Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Parathyroid Cancer Clinical Trials

A listing of Parathyroid Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (9) clinical trials

A clinical research study for the treatment of Parathyroid Adenoma, Hypocalcemia, Hyperparathyroidism

Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment. The principal diagnostic components are calcium in serum and urine and parathyroid hormone in serum. Patients with moderately to highly severe primary hyperparathyroidism will be treated. Treatment will be ...

Phase N/A

A clinical research study for the treatment of Parathyroid Adenoma, Thyroid Adenoma, Endocrine Tumors, Malignant neoplasm of adrenal gland, Neuroblastoma

Background Endocrine neoplasms are among the fastest growing tumors in incidence in the United States. Between 1995 and 2005, the incidence of thyroid carcinoma has increased 98 percent. Tumors of the thyroid, parathyroid, adrenal gland and pancreatic neuroendocrine tumors are among some of the most difficult tumors to clinically and ...

Phase N/A

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.


Optional Sub-study to Intraoperative Imaging With ICG Registry

The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.

Phase N/A

Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism

PRIMARY OBJECTIVES: I. Determine the non-inferiority of omission of parathyroid hormone (PTH) in patients who meet the biochemical and radiological criteria compared to current standard of care (i.e. use of intraoperative parathyroid hormone testing). SECONDARY OBJECTIVES: I. Cost-analysis to determine savings of omission of intraoperative PTH testing. OUTLINE Patients undergo ...

Phase N/A

Intra-operative Rapid Identification of Lymph Node and Parathyroid

In the experiment group, when suspicious parathyroid glands or lymph nodes were observed, a 22 G needle was applied for in situ puncture at a 45 degree angle. The needle was initially thrust into the gland for 0.2 mm, and then we advanced the needle for another 0.2mm while gently ...

Phase N/A

Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior

Data between the years of 1/1/2002 and 12/31/2013 will be analyzed. The medical records of all adult patients that had a parathyroidectomy for primary PHPT in MD Anderson Cancer Center will be screened in order to identify patients that had a histopathological diagnosis of parathyroid carcinoma or atypical parathyroid neoplasm.

Phase N/A

A Phase 2 clinical study for patients with Thyroid Adenoma, Testicular Non-Seminomatous Germ Cell Tumor, Malignant Odontogenic Neoplasm, Primary Peritoneal High Grade Serous Adenocarcinoma, Bladder Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Gastric Squamous Cell Carcinoma, Transitional cell carcinoma, Urethral Adenocarcinoma, Mucinous Adenocarcinoma, Nasal Cavity Adenocarcinoma, Paranasal Sinus Adenocarcinoma, Chordoma, Appendix Mucinous Adenocarcinoma, Anal Canal Neuroendocrine Carcinoma, Lung Carcinoid Tumor, Metaplastic Breast Carcinoma, Adrenocortical carcinoma, Mucinous cystadenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Major Salivary Gland Carcinoma, Extrahepatic Bile Duct Carcinoma, Adenoid Cystic Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Nasopharyngeal Papillary Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ureter Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Placental site trophoblastic tumor, Vulvar Adenocarcinoma, Parathyroid Adenoma, Ovarian Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Rare Diseases, Paraganglioma, Pheochromocytoma, Endometrial Transitional Cell Carcinoma, Seminoma, Undifferentiated Gastric Carcinoma, Vaginal Adenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Acinar Cell Carcinoma, Pseudomyxoma Peritonei, Mesodermal mixed tumor, Islet cell carcinoma, Serous cystadenocarcinoma, Minimally Invasive Lung Adenocarcinoma, Fallopian Tube Adenocarcinoma, Ureter Adenocarcinoma, Nasopharyngeal Cancer, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Spindle Cell Neoplasm, Colorectal Squamous Cell Carcinoma, Endometrioid carcinoma, Cervical Adenocarcinoma, Malignant Testicular Sex Cord-Stromal Tumor, Esophageal Undifferentiated Carcinoma, Paranasal Sinus Cancer, Placental Choriocarcinoma, Pituitary Adenoma, Aggressive fibromatosis, Fibromyxoid Tumor, Teratoma With Malignant Transformation, Vulvar Carcinoma, Ovarian Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Penis, Urethral Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Cholangiocarcinoma, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Nasopharyngeal Undifferentiated Carcinoma, Giant cell carcinoma, Dermoid Cyst, Gastric Neuroendocrine Carcinoma, Tracheal Carcinoma, Oral Cavity Carcinoma, Nerve Sheath Tumors, Lung Sarcomatoid Carcinoma, Nasal Cavity Carcinoma, Neoplasms, Unknown Primary, Anal Canal Undifferentiated Carcinoma, gastrointestinal stromal tumor, Oropharyngeal Undifferentiated Carcinoma

PRIMARY OBJECTIVES: I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. SECONDARY OBJECTIVES: I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free ...


Registry of Endocrine Tumors (Thyroid Parathyroid Adrenal Endocrine Pancreas Endocrine Digestive Tube)

The EUROCRINE project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-European database. Recording and accessing data at the European level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. Dissemination of ...

Phase N/A